Beroni Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BNIGF research report →
Price Chart
About the company
Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products, and a development pipeline targeting oncology and cell therapies. The company has operations in Australia, the United States, China, and Japan.
- CEO
- Boqing Zhang
- IPO
- 2019
- Employees
- 5
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on BNIGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $212.76K
- P/E
- -0.13
- PEG
- -0.00
- P/S
- 1.00
- P/B
- 0.09
- EV/EBITDA
- -1.13
- Div Yield
- 0.00%
- Gross Margin
- 98.42%
- Op Margin
- -3532.10%
- Net Margin
- -825.32%
- ROE
- -56.69%
- ROIC
- -165.23%
Latest fiscal year · YoY change
- Revenue
- $638.30K+101.5%
- Gross Profit
- $479.79K+113.4%
- Op Income
- $-4,704,582
- Net Income
- $-4,223,387+60.2%
- EPS
- $-0.13+71.7%
- OCF Growth
- +24.7%
- FCF Growth
- +25.5%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -1.76
- RSI (14)
- 100
- Avg Volume
- 18
No earnings-call transcripts are available for BNIGF yet.
- Free Float
- 0.2%
- Shares Outstanding
- 33.24M
- Float Shares
- 59.17K
Our BNIGF coverage
Recent articles, reports, and earnings notes.
No research on BNIGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BNIGF report →Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
globenewswire.com · Aug 18
Beroni Group Issues US$2 Million of Convertible Notes to Fund Research and Development Plans
globenewswire.com · May 28
Beroni Group's SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export Permit
globenewswire.com · Apr 27
Beroni Acquires Majority Interest in PENAO, an Anti-Cancer Drug Development Company
globenewswire.com · Feb 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.